Mod GRF 1-29 vs SHLP2
A detailed comparison to help you understand the differences and choose the right peptide for your research goals.
Mod GRF 1-29
Mod GRF 1-29 (Modified GRF 1-29, also called CJC-1295 without DAC or Tetrasubstituted GRF 1-29) is a modified growth hormone-releasing hormone analog with improved stability over natural GHRH.
Full details →SHLP2
SHLP2 (Small Humanin-Like Peptide 2) is a mitochondrial-derived peptide similar to humanin. It has shown insulin-sensitizing and cytoprotective effects in research, with potential metabolic benefits.
Full details →Side-by-Side Comparison
| Aspect | Mod GRF 1-29 | SHLP2 |
|---|---|---|
| Dose Range | 100 mcg–200 mcg | 1 mg–5 mg |
| Frequency | 3x daily | 1x daily |
| Cycle Length | 8–12 weeks | 4–8 weeks |
| Route | subcutaneous | subcutaneous |
| Mechanism | Binds to GHRH receptors in the pituitary gland to stimulate growth hormone release. Four amino acid substitutions improve resistance to enzymatic degradation while maintaining biological activity. | Enhances insulin sensitivity and glucose uptake. Provides cytoprotective effects similar to humanin. May act through similar but distinct receptor pathways. |
| Typical Dosage | Typical dosing: 100-300mcg administered 2-3 times daily, usually combined with a GHRP like Ipamorelin for synergistic effects. | Research compound with doses in the microgram to low milligram range studied in animal models. Human dosing not established. |
| Administration | Subcutaneous injection. Best administered on empty stomach. Short half-life (~30 minutes) necessitates multiple daily doses, unlike DAC version. | Subcutaneous or intraperitoneal injection in research settings. Various SHLP analogs (1-6) have different properties. |
| Side Effects | Flushing, headache, dizziness, and injection site reactions. Generally well-tolerated. May cause water retention. | Limited data. Animal studies suggest good tolerability. May affect glucose metabolism. |
| Best For |
What They Have in Common
Mod GRF 1-29, SHLP2 are both commonly used for:
Key Differences
Unique to Mod GRF 1-29:
Unique to SHLP2:
Which Has Stronger Evidence?
- Fat Loss: Mod GRF 1-29 has stronger research support.
| Goal | Mod GRF 1-29 | SHLP2 |
|---|---|---|
| Fat Loss | medium | low |
Key Studies
SHLP2
- Mitochondrial Peptide SHLP2 Limits Poly(I: C)-Induced Alveolar Epithelial Injury by Modulating Redox, Apoptotic, Inflammatory, and Inflammasome Responses.
Cytotechnology, 2026
- SHLP2 restores pre-osteoblastic cells against oxidative stress-induced inflammaging.
Scientific reports, 2025
- SHLP2 alleviates allergic asthma by inhibiting ETV5/GSDMD signaling pathway-mediated pyroptosis.
Cellular signalling, 2025
Ready to Learn More?
Looking for trusted sources?